表紙
市場調查報告書
商品編碼
613118

全球胰島素注射液市場:成長,趨勢,預測

HUMAN INSULIN DRUGS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 176 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球胰島素注射液市場相關調查,彙整市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的主要企業的簡介等相關資訊。

第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 市場趨勢

  • 市場概要
  • 推動市場的要素
  • 阻礙市場的要素
  • 波特的五力分析

第5章 市場區隔

  • 各產品類型
    • 基礎胰島素,長效型胰島素
    • 大劑量投藥型或速效型胰島素
    • 傳統胰島素注射液
    • 並用胰島素
    • 類似胰島素
  • 各地區
    • 北美
    • 歐洲
    • 南美
    • 亞太地區
    • 中東·非洲

第6章 市場指標

  • 第一型糖尿病人口
  • 第二型糖尿病人口

第7章 競爭環境

  • 企業簡介
    • Novo Nordisk AS
    • Sanofi Aventis
    • Eli Lilly
    • Biocon
    • Pfizer
    • Julphar
    • Exir
    • Sedico
    • Wockhardt
  • 企業佔有率分析

第8章 市場機會與未來趨勢

目錄
Product Code: 54429

The Human Insulin Drugs Market is expected to register a CAGR of 4.19% during the forecast period of 2020-2025 and is estimated to reach USD 29.9 billion by 2025. Diabetes is generally considered as a lifestyle-related disease. Over time, incidences of the disease have increased outrageously, with the increase in population around the world. Approximately 100 million people around the world need insulin, including all the people suffering from Type 1 diabetes and between 10-25% of people with Type 2 diabetes. Although insulin has been used in the treatment of diabetes for over 90 years, globally, more than half of those who need insulin today still cannot afford and access it. People with Type 1 diabetes need insulin therapy, which focuses on managing blood sugar levels, along with insulin, diet, and lifestyle, in order to prevent complications.

Key Market Trends

Growing Diabetes Prevalence Driving the Market

Approximately, 100 million people around the world need insulin, including all the people suffering from type-1 diabetes, and 10-25% of people with type-2 diabetes. Although insulin has been used in the treatment of diabetes across the world for over 90 years, more than half of the population in need of insulin today, still, cannot afford or access it. People with type-1 diabetes need insulin therapy, and the treatment focuses on managing blood sugar levels with insulin, diet, and lifestyle, to prevent complications. The R&D in the insulin segments are rising year-on-year, as researchers are trying to bring out the best molecule for patients' use, curbing out maximum side effects, and increasing their efficiency. Thus, the increasing prevalence of obesity and diabetes across the world is likely to augment considerable demand for insulin, which may drive the global market for insulin therapeutics.

North America Dominates the Market

North America dominates the global human insulin market, especially the United States, owing to the high prevalence of diabetes in the region because of a sedentary lifestyle. The cost factor is the major concern in the United States, where almost 50% of the insulin revenues for the manufacturers are from the country itself. The United States accounts for the highest sales of the long-acting insulin, Lantus, across the world. The majority of diabetic drug manufacturing companies consider the country as a critical market for improving overall global sales. Lantus is the most administered basal insulin across the world, accounting for a dominant share in the US market. The traditional North American human insulin drugs market is expected to grow during the forecast period, due to its economic affordability by patients. Humulin holds the highest market share, followed by Novolin. There are no generic competitors for the traditional North American human insulin drugs market in the United States.

Competitive Landscape

The global human insulin market is highly consolidated with three major manufacturers holding a global market presence, and the remaining manufacturers confining to the other local or region-specific manufacturers. Mergers and acquisitions that happened between the players in the recent past have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (Insulin Glargine).

Insulins under development:

Novo Nordisk is developing a first once-weekly long-acting insulin (LAI287) which is currently in phase 2. The insulin is indicated for both type-1 and type-2 diabetes patients. Eli Lilly is developing a long-acting insulin-Fc (LY3209590). "Basal insulin-Fc" is a large molecule comprised of engineered insulin fused to an Fc domain designed to provide a long-acting basal profile. LY3209590 is being studied for the treatment of diabetes.

Oral Insulin's Drugs will boost the market:

Biocon is developing Insulin Tregopil, an oral prandial insulin tablet, for the treatment of type-1 and type-2 diabetes mellitus. The fast-acting oral insulin could improve post-prandial glucose control with reduced side effects and greater adherence, thus holding the promise to transform T1D management. Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company, focused on the development of oral drug delivery systems, is working to bring the first oral insulin product to market, thus, providing a more convenient, effective, as well as a safer method for delivering insulin therapy.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2025)
      • 5.1.1.1 Lantus (Insulin glargine)
      • 5.1.1.2 Levemir (Insulin detemir)
      • 5.1.1.3 Toujeo (Insulin glargine)
      • 5.1.1.4 Tresiba (Insulin degludec)
      • 5.1.1.5 Basaglar (Insulin glargine)
    • 5.1.2 Bolus or Fast-acting Insulins (Value and Volume, 2012-2025)
      • 5.1.2.1 NovoRapid/Novolog (Insulin aspart)
      • 5.1.2.2 Humalog (Insulin lispro)
      • 5.1.2.3 Apidra (Insulin glulisine)
      • 5.1.2.4 FIASP (Insulin aspart)
      • 5.1.2.5 Admelog (Insulin lispro)
    • 5.1.3 Traditional Human Insulins (Value and Volume, 2012-2025)
      • 5.1.3.1 Novolin/Actrapid/Insulatard
      • 5.1.3.2 Humulin
      • 5.1.3.3 Insuman
    • 5.1.4 Combination Insulins (Value and Volume, 2012-2025)
      • 5.1.4.1 NovoMix (Biphasic Insulin aspart)
      • 5.1.4.2 Ryzodeg (Insulin degludec/Insulin aspart)
      • 5.1.4.3 Xultophy (Insulin degludec/Liraglutide)
      • 5.1.4.4 Soliqua/Suliqua (Insulin glargine/Lixisenatide)
    • 5.1.5 Biosimilar Insulins (Value and Volume, 2012-2025)
      • 5.1.5.1 Insulin Glargine Biosimilars
      • 5.1.5.2 Human Insulin Biosimilars
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States (Value and Volume, 2012-2025)
      • 5.2.1.1.1 Basal or Long-acting Insulins
      • 5.2.1.1.2 Bolus or Fast-acting Insulins
      • 5.2.1.1.3 Traditional Human Insulins
      • 5.2.1.1.4 Combination Insulins
      • 5.2.1.1.5 Biosimilar Insulins
      • 5.2.1.2 Canada (Value and Volume, 2012-2025)
      • 5.2.1.2.1 Basal or Long-acting Insulins
      • 5.2.1.2.2 Bolus or Fast-acting Insulins
      • 5.2.1.2.3 Traditional Human Insulins
      • 5.2.1.2.4 Combination Insulins
      • 5.2.1.2.5 Biosimilar Insulins
      • 5.2.1.3 Rest of North America (Value and Volume, 2012-2025)
      • 5.2.1.3.1 Basal or Long-acting Insulins
      • 5.2.1.3.2 Bolus or Fast-acting Insulins
      • 5.2.1.3.3 Traditional Human Insulins
      • 5.2.1.3.4 Combination Insulins
      • 5.2.1.3.5 Biosimilar Insulins
    • 5.2.2 Europe
      • 5.2.2.1 France (Value and Volume, 2012-2025)
      • 5.2.2.1.1 Basal or Long-acting Insulins
      • 5.2.2.1.2 Bolus or Fast-acting Insulins
      • 5.2.2.1.3 Traditional Human Insulins
      • 5.2.2.1.4 Combination Insulins
      • 5.2.2.1.5 Biosimilar Insulins
      • 5.2.2.2 Germany (Value and Volume, 2012-2025)
      • 5.2.2.2.1 Basal or Long-acting Insulins
      • 5.2.2.2.2 Bolus or Fast-acting Insulins
      • 5.2.2.2.3 Traditional Human Insulins
      • 5.2.2.2.4 Combination Insulins
      • 5.2.2.2.5 Biosimilar Insulins
      • 5.2.2.3 Italy (Value and Volume, 2012-2025)
      • 5.2.2.3.1 Basal or Long-acting Insulins
      • 5.2.2.3.2 Bolus or Fast-acting Insulins
      • 5.2.2.3.3 Traditional Human Insulins
      • 5.2.2.3.4 Combination Insulins
      • 5.2.2.3.5 Biosimilar Insulins
      • 5.2.2.4 Spain (Value and Volume, 2012-2025)
      • 5.2.2.4.1 Basal or Long-acting Insulins
      • 5.2.2.4.2 Bolus or Fast-acting Insulins
      • 5.2.2.4.3 Traditional Human Insulins
      • 5.2.2.4.4 Combination Insulins
      • 5.2.2.4.5 Biosimilar Insulins
      • 5.2.2.5 United Kingdom (Value and Volume, 2012-2025)
      • 5.2.2.5.1 Basal or Long-acting Insulins
      • 5.2.2.5.2 Bolus or Fast-acting Insulins
      • 5.2.2.5.3 Traditional Human Insulins
      • 5.2.2.5.4 Combination Insulins
      • 5.2.2.5.5 Biosimilar Insulins
      • 5.2.2.6 Russia (Value and Volume, 2012-2025)
      • 5.2.2.6.1 Basal or Long-acting Insulins
      • 5.2.2.6.2 Bolus or Fast-acting Insulins
      • 5.2.2.6.3 Traditional Human Insulins
      • 5.2.2.6.4 Combination Insulins
      • 5.2.2.6.5 Biosimilar Insulins
      • 5.2.2.7 Rest of Europe (Value and Volume, 2012-2025)
      • 5.2.2.7.1 Basal or Long-acting Insulins
      • 5.2.2.7.2 Bolus or Fast-acting Insulins
      • 5.2.2.7.3 Traditional Human Insulins
      • 5.2.2.7.4 Combination Insulins
      • 5.2.2.7.5 Biosimilar Insulins
    • 5.2.3 Latin America
      • 5.2.3.1 Mexico (Value and Volume, 2012-2025)
      • 5.2.3.1.1 Basal or Long-acting Insulins
      • 5.2.3.1.2 Bolus or Fast-acting Insulins
      • 5.2.3.1.3 Traditional Human Insulins
      • 5.2.3.1.4 Combination Insulins
      • 5.2.3.1.5 Biosimilar Insulins
      • 5.2.3.2 Brazil (Value and Volume, 2012-2025)
      • 5.2.3.2.1 Basal or Long-acting Insulins
      • 5.2.3.2.2 Bolus or Fast-acting Insulins
      • 5.2.3.2.3 Traditional Human Insulins
      • 5.2.3.2.4 Combination Insulins
      • 5.2.3.2.5 Biosimilar Insulins
      • 5.2.3.3 Rest of Latin America (Value and Volume, 2012-2025)
      • 5.2.3.3.1 Basal or Long-acting Insulins
      • 5.2.3.3.2 Bolus or Fast-acting Insulins
      • 5.2.3.3.3 Traditional Human Insulins
      • 5.2.3.3.4 Combination Insulins
      • 5.2.3.3.5 Biosimilar Insulins
    • 5.2.4 Asia-Pacific
      • 5.2.4.1 Japan (Value and Volume, 2012-2025)
      • 5.2.4.1.1 Basal or Long-acting Insulins
      • 5.2.4.1.2 Bolus or Fast-acting Insulins
      • 5.2.4.1.3 Traditional Human Insulins
      • 5.2.4.1.4 Combination Insulins
      • 5.2.4.1.5 Biosimilar Insulins
      • 5.2.4.2 South Korea (Value and Volume, 2012-2025)
      • 5.2.4.2.1 Basal or Long-acting Insulins
      • 5.2.4.2.2 Bolus or Fast-acting Insulins
      • 5.2.4.2.3 Traditional Human Insulins
      • 5.2.4.2.4 Combination Insulins
      • 5.2.4.2.5 Biosimilar Insulins
      • 5.2.4.3 China (Value and Volume, 2012-2025)
      • 5.2.4.3.1 Basal or Long-acting Insulins
      • 5.2.4.3.2 Bolus or Fast-acting Insulins
      • 5.2.4.3.3 Traditional Human Insulins
      • 5.2.4.3.4 Combination Insulins
      • 5.2.4.3.5 Biosimilar Insulins
      • 5.2.4.4 India (Value and Volume, 2012-2025)
      • 5.2.4.4.1 Basal or Long-acting Insulins
      • 5.2.4.4.2 Bolus or Fast-acting Insulins
      • 5.2.4.4.3 Traditional Human Insulins
      • 5.2.4.4.4 Combination Insulins
      • 5.2.4.4.5 Biosimilar Insulins
      • 5.2.4.5 Australia (Value and Volume, 2012-2025)
      • 5.2.4.5.1 Basal or Long-acting Insulins
      • 5.2.4.5.2 Bolus or Fast-acting Insulins
      • 5.2.4.5.3 Traditional Human Insulins
      • 5.2.4.5.4 Combination Insulins
      • 5.2.4.5.5 Biosimilar Insulins
      • 5.2.4.6 Vietnam (Value and Volume, 2012-2025)
      • 5.2.4.6.1 Basal or Long-acting Insulins
      • 5.2.4.6.2 Bolus or Fast-acting Insulins
      • 5.2.4.6.3 Traditional Human Insulins
      • 5.2.4.6.4 Combination Insulins
      • 5.2.4.6.5 Biosimilar Insulins
      • 5.2.4.7 Malaysia (Value and Volume, 2012-2025)
      • 5.2.4.7.1 Basal or Long-acting Insulins
      • 5.2.4.7.2 Bolus or Fast-acting Insulins
      • 5.2.4.7.3 Traditional Human Insulins
      • 5.2.4.7.4 Combination Insulins
      • 5.2.4.7.5 Biosimilar Insulins
      • 5.2.4.8 Indonesia (Value and Volume, 2012-2025)
      • 5.2.4.8.1 Basal or Long-acting Insulins
      • 5.2.4.8.2 Bolus or Fast-acting Insulins
      • 5.2.4.8.3 Traditional Human Insulins
      • 5.2.4.8.4 Combination Insulins
      • 5.2.4.8.5 Biosimilar Insulins
      • 5.2.4.9 Philippines (Value and Volume, 2012-2025)
      • 5.2.4.9.1 Basal or Long-acting Insulins
      • 5.2.4.9.2 Bolus or Fast-acting Insulins
      • 5.2.4.9.3 Traditional Human Insulins
      • 5.2.4.9.4 Combination Insulins
      • 5.2.4.9.5 Biosimilar Insulins
      • 5.2.4.10 Thailand (Value and Volume, 2012-2025)
      • 5.2.4.10.1 Basal or Long-acting Insulins
      • 5.2.4.10.2 Bolus or Fast-acting Insulins
      • 5.2.4.10.3 Traditional Human Insulins
      • 5.2.4.10.4 Combination Insulins
      • 5.2.4.10.5 Biosimilar Insulins
      • 5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2025)
      • 5.2.4.11.1 Basal or Long-acting Insulins
      • 5.2.4.11.2 Bolus or Fast-acting Insulins
      • 5.2.4.11.3 Traditional Human Insulins
      • 5.2.4.11.4 Combination Insulins
      • 5.2.4.11.5 Biosimilar Insulins
    • 5.2.5 Middle-East and Africa
      • 5.2.5.1 Saudi Arabia (Value and Volume, 2012-2025)
      • 5.2.5.1.1 Basal or Long-acting Insulins
      • 5.2.5.1.2 Bolus or Fast-acting Insulins
      • 5.2.5.1.3 Traditional Human Insulins
      • 5.2.5.1.4 Combination Insulins
      • 5.2.5.1.5 Biosimilar Insulins
      • 5.2.5.2 Iran (Value and Volume, 2012-2025)
      • 5.2.5.2.1 Basal or Long-acting Insulins
      • 5.2.5.2.2 Bolus or Fast-acting Insulins
      • 5.2.5.2.3 Traditional Human Insulins
      • 5.2.5.2.4 Combination Insulins
      • 5.2.5.2.5 Biosimilar Insulins
      • 5.2.5.3 Egypt (Value and Volume, 2012-2025)
      • 5.2.5.3.1 Basal or Long-acting Insulins
      • 5.2.5.3.2 Bolus or Fast-acting Insulins
      • 5.2.5.3.3 Traditional Human Insulins
      • 5.2.5.3.4 Combination Insulins
      • 5.2.5.3.5 Biosimilar Insulins
      • 5.2.5.4 Oman (Value and Volume, 2012-2025)
      • 5.2.5.4.1 Basal or Long-acting Insulins
      • 5.2.5.4.2 Bolus or Fast-acting Insulins
      • 5.2.5.4.3 Traditional Human Insulins
      • 5.2.5.4.4 Combination Insulins
      • 5.2.5.4.5 Biosimilar Insulins
      • 5.2.5.5 South Africa (Value and Volume, 2012-2025)
      • 5.2.5.5.1 Basal or Long-acting Insulins
      • 5.2.5.5.2 Bolus or Fast-acting Insulins
      • 5.2.5.5.3 Traditional Human Insulins
      • 5.2.5.5.4 Combination Insulins
      • 5.2.5.5.5 Biosimilar Insulins
      • 5.2.5.6 Rest of Middle-East and Africa (Value and Volume, 2012-2025)
      • 5.2.5.6.1 Basal or Long-acting Insulins
      • 5.2.5.6.2 Bolus or Fast-acting Insulins
      • 5.2.5.6.3 Traditional Human Insulins
      • 5.2.5.6.4 Combination Insulins
      • 5.2.5.6.5 Biosimilar Insulins

6 MARKET INDICATORS

  • 6.1 Type 1 Diabetes Population (2012-2025)
  • 6.2 Type 2 Diabetes Population (2012-2025)

7 COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Novo Nordisk A/S
      • 7.1.1.1 Overview
      • 7.1.1.2 Products and Strategies
      • 7.1.1.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
      • 7.1.1.4 Ratio Analysis (5 Years)
      • 7.1.1.5 Strength and Stability Analysis (5 Years)
      • 7.1.1.6 Recent Developments
    • 7.1.2 Sanofi S.A.
      • 7.1.2.1 Overview
      • 7.1.2.2 Products and Strategies
      • 7.1.2.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
      • 7.1.2.4 Ratio Analysis (5 Years)
      • 7.1.2.5 Strength and Stability Analysis (5 Years)
      • 7.1.2.6 Recent Developments
    • 7.1.3 Eli Lilly and Company
      • 7.1.3.1 Overview
      • 7.1.3.2 Products and Strategies
      • 7.1.3.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
      • 7.1.3.4 Ratio Analysis (5 Years)
      • 7.1.3.5 Strength and Stability Analysis (5 Years)
      • 7.1.3.6 Recent Developments
    • 7.1.4 Biocon Limited
      • 7.1.4.1 Overview
      • 7.1.4.2 Products and Strategies
      • 7.1.4.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
      • 7.1.4.4 Ratio Analysis (5 Years)
      • 7.1.4.5 Strength and Stability Analysis (5 Years)
      • 7.1.4.6 Recent Developments
    • 7.1.5 Pfizer Inc.
      • 7.1.5.1 Overview
      • 7.1.5.2 Products and Strategies
      • 7.1.5.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
      • 7.1.5.4 Ratio Analysis (5 Years)
      • 7.1.5.5 Strength and Stability Analysis (5 Years)
      • 7.1.5.6 Recent Developments
    • 7.1.6 Wockhardt
      • 7.1.6.1 Overview
      • 7.1.6.2 Products and Strategies
      • 7.1.6.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
      • 7.1.6.4 Ratio Analysis (5 Years)
      • 7.1.6.5 Strength and Stability Analysis (5 Years)
      • 7.1.6.6 Recent Developments
    • 7.1.7 Julphar
      • 7.1.7.1 Overview
      • 7.1.7.2 Products and Strategies
      • 7.1.7.3 Recent Developments
    • 7.1.8 Exir
      • 7.1.8.1 Overview
      • 7.1.8.2 Products and Strategies
      • 7.1.8.3 Recent Developments
    • 7.1.9 Sedico
      • 7.1.9.1 Overview
      • 7.1.9.2 Products and Strategies
      • 7.1.9.3 Recent Developments
  • 7.2 COMPANY SHARE ANALYSIS
    • 7.2.1 Novo Nordisk AS
    • 7.2.2 Sanofi Aventis
    • 7.2.3 Eli Lilly
    • 7.2.4 Other Companies

8 MARKET OPPORTUNITIES AND FUTURE TRENDS